Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [30] [27] [31] [32] It is specifically used for cancer that is HER2 receptor positive. [30] It may be used by itself or together with other chemotherapy medication. [30]

Mechanism of action. Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Over-expressed in breast tumour cells, HER-2 overamplifies the signal provided by other receptors of the HER family by forming heterodimers 4. The HER-2 ...

Learn about the mechanism of action for Herceptin® (trastuzumab) and how it's designed to work treating HER2+ Metastatic Breast Cancer. See Full Safety and Boxed Warnings for more information.

Sep 1, 2011 · SUMMARY: Herceptin (trastuzumab) is a human monoclonal antibody that interferes with the HER2 receptor. It is currently the only FDA-approved therapeutic antibody for HER2-positive breast cancer. This article will present the mechanism at action as well as the clinical role at this monoclonal antibody.

One such medication is trastuzumab (Herceptin, Genentech), a humanized monoclonal antibody. Trastuzumab binds to the extracellular juxtamembrane domain of HER2 and inhibits the proliferation...

Jul 15, 2021 · Studies show that trastuzumab suppresses HER2 receptors’ oncogenic functions in HER2-postive tumors. Moreover, trastuzumab has been shown to provoke immune responses against the HER2-amplified tumors. Trastuzumab as a first HER2-targeted therapy for the treatment of HER2-positive breast cancer patients was introduced in 1998.

Jun 15, 2022 · Herceptin is an effective treatment for breast cancer for the reason that it binds to the extracellular domain of HER2 and by multiple mechanisms of action can prevent cell proliferation as well as target these HER2+ cells for destruction by the immune system [3] [10].

Herceptin: Mechanisms of Action. (Upper portion) Herceptin binds to the extracellular domain of the HER-2 protein, which is in a homodimer or heterodimer with another receptor. Upon binding, several molecular mechanisms become activated.

However, the majority of cancers that initially respond to Herceptin begin to progress again within 1 year. This review describes mechanisms by which Herceptin inhibits cell growth in breast cancers that overexpress HER-2 and highlights possible mechanisms contributing to …

Jun 18, 2012 · Trastuzumab (or Herceptin) was developed by Genentech Inc (San Francisco, CA, USA) as a recombinant humanized monoclonal antibody directed against the extracellular domain IV of HER2 (Carter et al., 1992), has served as a remarkable example of a successful targeted therapy in breast cancer.